AI Article Synopsis
- iTLPD-GI is a rare type of clonal T-cell cancer found in the gastrointestinal (GI) organs and is now officially recognized in the WHO Classification.
- There is significant variation in its pathological and molecular characteristics, making accurate diagnosis crucial as it requires different treatment compared to more common GI lymphomas.
- The review focuses on defining iTLPD-GI, identifying effective diagnostic biomarkers, and addressing challenges in distinguishing it from other similar disorders.
Article Abstract
iTLPD-GI is a low-grade clonal T-cell lymphoproliferative disease arising in GI organs. It is an uncommon disease, and only recently has it been enlisted as a distinct provisional entity in the current WHO Classification. Data from the literature disclose high heterogeneity in terms of pathological and molecular features; on the other hand, establishing an accurate diagnosis of iTLPD-GI is of pivotal importance, since treatment options are different from that of other, more frequent lymphomas that arise in the gastrointestinal tract. In this review, we aimed to better define this novel entity, and to identify useful diagnostic biomarkers; moreover, we provide a biomarker-based approach to the diagnosis and describe the most common issues in differentiating iTLPD-GI from other neoplastic and non-neoplastic disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199971 | PMC |
| http://dx.doi.org/10.3390/cancers13112790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!